MAM
KROS icon

Martingale Asset Management’s Keros Therapeutics KROS Stock Holding History

Martingale Asset Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$725K Buy
67,796
+20,200
+42% +$225K 0.02% 588
2026
Q1 		$525K Buy
47,596
+8,217
+21% +$127K 0.01% 625
2025
Q4 		$802K Buy
39,379
+202
+0.5% +$3.54K 0.02% 512
2025
Q3 		$620K Buy
39,177
+25,319
+183% +$374K 0.02% 579
2025
Q2 		$185K Buy
+13,858
New +$187K ﹤0.01% 762

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Martingale Asset Management's KROS Position: Q2 2026 in Review

Martingale Asset Management increased its Keros Therapeutics (KROS) stake by 42% in Q2 2026, buying an estimated $225K and bringing the position to 67,796 shares worth $725K. The position accounts for 0.02% of the portfolio, ranked #588.

Martingale Asset Management first reported a position in KROS in Q2 2025 and has held it in 5 quarters since. The position peaked at $802K in Q4 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Martingale Asset Management held 67,796 shares of Keros Therapeutics worth $725K as of Q2 2026.
  • Martingale Asset Management bought 20,200 Keros Therapeutics shares in Q2 2026, an estimated $225K.
  • Keros Therapeutics made up 0.02% of Martingale Asset Management's portfolio in Q2 2026, its #588 holding.
  • Martingale Asset Management first reported a position in Keros Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Martingale Asset Management's Keros Therapeutics position peaked at $802K in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.